AAAAAA
Results:
1-18
|
Results: 18
Authors:
Gattis, WA
Citation: Wa. Gattis, Metoprolol CR/XL in the treatment of chronic heart failure, PHARMACOTHE, 21(5), 2001, pp. 604-613
Authors:
Serebruany, VL
Alford, AB
Meister, AF
Fuzaylov, SY
Gattis, WA
Gurbel, PA
O'Connor, CM
Citation: Vl. Serebruany et al., Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial), THROMB RES, 101(6), 2001, pp. 427-433
Authors:
Whellan, DJ
Gaulden, L
Gattis, WA
Granger, B
Russell, SD
Blazing, MA
Cuffe, MS
O'Connor, CM
Citation: Dj. Whellan et al., The benefit of implementing a heart failure disease management program, ARCH IN MED, 161(18), 2001, pp. 2223-2228
Authors:
O'Connor, CM
Gattis, WA
Hellkamp, AS
Langer, A
Larsen, RL
Harrington, RA
Berkowitz, SD
O'Gara, PT
Kopecky, SL
Gheorghiade, M
Daly, R
Califf, RM
Fuster, V
Citation: Cm. O'Connor et al., Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS), AM J CARD, 88(5), 2001, pp. 541-546
Authors:
Gattis, WA
Galanos, A
O'Connor, CM
Citation: Wa. Gattis et al., Angiotensin-converting enzyme heart failure: What is optimal?, AM HEART J, 141(3), 2001, pp. 331-333
Authors:
Gattis, WA
Citation: Wa. Gattis, Practical issues in the treatment of patients with heart failure, PHARMACOTHE, 20(11), 2000, pp. 385S-391S
Authors:
Davis, CJ
Gurbel, PA
Gattis, WA
Fuzaylov, SY
Nair, GV
O'Connor, SM
Serebruany, VL
Citation: Cj. Davis et al., Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge, INT J CARD, 75(1), 2000, pp. 15-21
Authors:
O'Connor, CM
Gattis, WA
Shaw, L
Cuffe, MS
Califf, RM
Citation: Cm. O'Connor et al., Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function, AM J CARD, 86(8), 2000, pp. 863-867
Authors:
O'Connor, CM
Gattis, WA
Ryan, TJ
Citation: Cm. O'Connor et al., The role of clinical nonfatal end points in cardiovascular Phase II/III clinical trials, AM HEART J, 139(4), 2000, pp. S143-S154
Authors:
O'Connor, CM
Gattis, WA
Zannad, F
McNulty, SE
Gheorghiade, M
Adams, KF
Califf, RM
McKenna, WJ
Soler-Soler, J
Swedberg, K
Citation: Cm. O'Connor et al., Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes, EUR J HE FA, 1(1), 1999, pp. 81-88
Authors:
Whellan, DJ
Gattis, WA
Gaulden, L
Granger, B
O'Connor, CM
Citation: Dj. Whellan et al., Disease management of congestive heart failure, AM J M CARE, 5(4), 1999, pp. 499-507
Authors:
Terra, SG
Washam, JB
Dunham, GD
Gattis, WA
Citation: Sg. Terra et al., Therapeutic range of digoxin's efficacy in heart failure: What is the evidence?, PHARMACOTHE, 19(10), 1999, pp. 1123-1126
Authors:
O'Connor, CM
Gattis, WA
Swedberg, K
Citation: Cm. O'Connor et al., Current and novel pharmacologic approaches in advanced heart failure, HEART LUNG, 28(4), 1999, pp. 227-242
Authors:
McKenzie, ME
Pothula, A
Gurbel, PA
Fuzaylov, SY
O'Connor, CM
Gattis, WA
Serebruany, VL
Citation: Me. Mckenzie et al., Failure of thrombin generation markers to triage patients presenting with chest pain, CARDIOLOGY, 92(1), 1999, pp. 53-58
Authors:
Gattis, WA
Hasselblad, V
Whellan, DJ
O'Connor, CM
Citation: Wa. Gattis et al., Reduction in heart failure events by the addition of a clinical pharmacistto the heart failure management team - Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study, ARCH IN MED, 159(16), 1999, pp. 1939-1945
Authors:
Nair, GV
Gurbel, PA
O'Connor, CM
Gattis, WA
Murugesan, SR
Serebruany, VL
Citation: Gv. Nair et al., Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors, AM J CARD, 84(3), 1999, pp. 321
Authors:
O'Connor, CM
Gattis, WA
Gheorghiade, M
Granger, CB
Gilbert, J
McKenney, JM
Messineo, FC
Burnett, JC
Katz, SD
Elkayam, U
Kasper, EK
Goldstein, S
Cody, RJ
Massie, BM
Citation: Cm. O'Connor et al., A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: The US Ecadotril Pilot Safety Study, AM HEART J, 138(6), 1999, pp. 1140-1148
Authors:
O'Connor, CM
Gattis, WA
Uretsky, BF
Adams, KF
McNulty, SE
Grossman, SH
McKenna, WJ
Zannad, F
Swedberg, K
Gheorghiada, M
Califf, RM
Citation: Cm. O'Connor et al., Continuous intravenous dobutamine is associated with an increased risk of death in patients advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST), AM HEART J, 138(1), 1999, pp. 78-86
Risultati:
1-18
|